The ability of PRSER+ to discriminate between controls and breast cancer cases was estimated as an AUC of 0.60 (95% CI = 0.51 to 0.69) for BRCA1 and 0.59 (95% CI = 0.55 to 0.63) for BRCA2 carriers. This evidence concerns the gene BRCA2 and breast carcinoma.